Toxicity Study of 3-Thienylalanine- Ornithine-Proline (TOP) Using as Novel ACE Inhibitor-Reference-Cited by-同舟云学术

Toxicity Study of 3-Thienylalanine- Ornithine-Proline (TOP) Using as Novel ACE Inhibitor

Published:2022-09-03 Issue:5 Volume:28 Page:
ISSN:1573-3904
Container-title:International Journal of Peptide Research and Therapeutics
language:en
Short-container-title:Int J Pept Res Ther

Author:

Seth Mahesh Kumar,Singh Rakesh Kumar,Hussain M. Ejaz,Pasha Santosh,Fahim Mohammad

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Molecular Medicine,Biochemistry,Bioengineering,Analytical Chemistry

Link

https://link.springer.com/content/pdf/10.1007/s10989-022-10449-3.pdf

Reference47 articles.

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981–2997

2. Al-Mamary M, Al-Habori M, Al-AghbariAM BMM (2002) Investigation into the toxicological effects of Catha edulis leaves: a short -term study in animals. Phytother Res 16:127–132

3. Androulakis ES et al (2009) Essential hypertension: is there a role for inflammatory mechanisms. Cardiol Rev 17(5):216–221

4. Anon (1999) Canadian led landmark study demonstrates ACE inhibitor ramipril reduces risk of cardiovascular death and life-threatening events. Can J Cardiol 15(9):1027

5. Bala M, Gupta S, Pasha MAQ (2000) Angiotensin converting enzyme assay optimization: Influence of various buffers and their concentrations. Clin Biochem 33:687–689